Guaifenesin

Selected References:

  • Aselton P, et al. 1985. First-trimester drug use and congenital disorders. Obstet Gynecol 65:451-5.
  • Check J, et al. 1982. Improvement of cervical mucus factor with guaifenesin. Fertility and Sterility, 37(5): 707-708.
  • Briggs GG, et al. 2017. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Cao Y, et al. 2021. Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case-control study. BMJ Open, 11: e053604.
  • Check JH, et al. 1982. Improvement of cervical factor with guaifenesin. Fertil Steril 37:707-8.
  • Dicpinigattis, et al. 2003. Effects of guaifenesin on cough reflex and sensitivity. Chest Journal, 126(6): 2178-2181.
  • Dude C, et al. 2021. Assessment of the Safety of Common Medications Used During Pregnancy. JAMA, 326(23):2421-2422.
  • Heinonen OP, et al. 1977. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group.
  • Means G, et al. 2010. Guaifenesin and increased sperm motility: a preliminary case report. Int J Gen Med, 4: 13-14.
  • PDR.Net. 2024. Guaifenesin-Drug Summary. PDR.Net Accessed December 10, 2024. https://www.pdr.net/drug-summary/Mucinex-guaifenesin-1275.
  • Servey J, et al. 2014, Over-the-Counter Medications in Pregnancy. Am Fam Physician, 90(8):548-55.
  • Shaw G, et al. 1998. Maternal illness, including fever, and medication use as risk factors for neural tube defects. Teratology, 57: 1-7.
  • Silva R, Lee J, et al. 2007. Is guaifenesin safe during pregnancy? J. Family Practice 56 (8): 669-670.

Guaifenesin

Selected References:

  • Amato MP, et al. 2015. Fertility, pregnancy and childbirth in patients with multiple sclerosis: Impact of disease-modifying drugs. CNS Drugs. 29:207–220.
  • Andersen JB, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. Eur J Neurol 30(1):162-171.
  • Bridel C, et al. 2014. Update on multiple sclerosis treatments. Swiss Med Wkly. 144:w14012.
  • Ciplea AI, et al. 2020. Dimethyl fumarate transfer into breast milk. Ther Adv Neurol Disord. 13:1756286420968414.
  • Gold R, et al. 2015. Delayed-release dimethyl fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 4(2):93-104.
  • Hellwig K, et al. 2024. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. Mult Scler 30(2):209-215.
  • Landi D, et al. 2024. Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. Mult Scler 30(11-12):1503-1513.
  • Leroy C, et al. 2015. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 10:136.
  • Lu E, et al. 2014. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs; 28(2):89-94.
  • Moccia M, et al. 2023. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. J Neurol Neurosurg Psychiatry.94(9):689-697.
  • Tecfidera prescribing information. 2024. Available online at: https://www.tecfiderahcp.com/content/dam/commercial/multiple-sclerosis/tecfidera/hcp/en_us/pdf/Tecfidera_PI.pdf.
  • Van Neste M, et al. 20 Very low monomethyl fumarate exposure via human milk: a case report-a contribution from the ConcePTION project. Front Public Health. 2;12:1393752.
  • Yeh WZ, et al. 2021. Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. Neurology. 96(24):e2989-e3002.

Guaifenesin

Selected References:

  • Alwan S, et al. 2005. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 73:123-130.
  • Bass JK, Faix RG. 2006. Gestational Therapy with an Angiotensin II Receptor Antagonist and Transient Renal Failure in a Premature Infant. Am J Perinatol. 23:313-318.
  • Centers for Disease Control and Prevention. 2020. Facts about craniosynostosis. Centers for Disease Control and Prevention. Available oneline at https://www.cdc.gov/ncbddd/birthdefects/craniosynostosis.html. [Accessed Jan 2023].
  • Daikha-Dahmane F, et al. 2006. Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol. 21(5):729-32.
  • Diav-Citrin O, et al. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol. 31(4):540-545.
  • Gersak K, et al. 2009. Angiotensin II receptor blockers in pregnancy: a report of 5 cases. Reprod Toxicol. 28(1):109-12.
  • Lambot M, et al. 2001. Angiotensin-II-receptor inhibitors in pregnancy. Lancet. 357:1619-1620.
  • Marin EC, et al. 2014. The role of oxidative stress in renal injury induced in rats by losartan exposure during lactation. J Renin Angiotensin Aldosterone Syst. 15(4): 362-377.
  • Martinovic J, et al. 2001. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet. 358:241-242.
  • Mulla S, Siddiqui WJ. Losartan. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
  • Saji H, et al. 2001. Losartan and fetal toxic effects. Lancet. 357:363.
  • Schaefer C. 2003. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol. 67:591-594.
  • Sergesketter AR, et al. 2019. Characterization of Perinatal Risk Factors and Complications Associated with Nonsyndromic Craniosynostosis. J Craniofac Surg; 30(2):334-338.
  • Serreau R, et al. 2005. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG. 112(6):710-712.
  • Sica DA, et al. 2005. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 44(8):797-814.
  • Spaggiari E, et al. 2012. Renin-Angiotensin System Blockers Study Group, Muller F. Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers. Prenat Diagn. 18:1-6.
  • Spence SG, et al. 1995. Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology. 51:383-97.
  • Stevenson KM, et al. 1996. Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep. Clin Exp Pharmacol Physiol. 23:125-33.
  • Wei Q, et al. 2021. Use of angiotensin II receptor blocker during pregnancy: A case report. Medicine (Baltimore). 22;100(3):e24304.
  • Xie M, et al. 2023. Efficacy of single-pill combination in uncontrolled essential hypertension: a systematic review and network meta-analysis. Clin Cardiol, 46:886-898.American College of Obstetricians and Gynecologists (ACOG). 2018. Committee Opinion No. 753: Assessment and Treatment of Pregnant Women with Suspected or Confirmed Influenza. Obstet Gyn 132(4):e169-e173.

Guaifenesin

Selected References:  

  • Andrade C. 2022 Psychotropic drugs with long half-lives: implications for drug discontinuation, occasional missed doses, dosing interval, and pregnancy planning. J Clin Psychiatry, 83:22f14593. 
  • Athinarayanan P, et al. 1976. Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol, 124:212-213. 
  • Crombie DL, et al. 1975. Fetal effects of tranquilizers in pregnancy. New Eng J Med, 293:198-199. 
  • Czeizel A. 1988. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol, 1:183-188. 
  • Czeizel AE, et al. 1997. Teratologic evaluation of 178 infants born to mothers who attempted suicide by drugs during pregnancy. Obstet Gynecol, 90:195-201. 
  • Czeizel AE, et al. 2004. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicology & Teratology, 26(4):593-598. 
  • Czeizel AE, Mosonyi A. 1997. Monitoring of early human fetal development in women exposed to large doses of chemicals. Environ Mol Mutagen, 30:240-244.  
  • Gidai J, et al. 2008. A study of the teratogenic and fetotoxic effects of large doses of chlordiazepoxide used for self-poisoning by 35 pregnant women. Toxicol Ind Health, 24(1-2):41-51. 
  • Hartz SC, et al. 1975. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development and childhood mortality. New Eng J Med, 292:726-728. 
  • Hughes JM. 1964. Failure to ejaculate with chlordiazepoxide. Am J Psychiatry, 121:610-611. 
  • Martino V, Mas M, Davidson JM. 1987. Chlordiazepoxide facilitates erections and inhibits seminal emission in rats. Psychopharmacology, 91:85-89. 
  • Milkovich L, Van den Berg BJ. 1974. Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. New Eng J Med, 291:1268-1271.  
  • Stirrat GM, et al. 1974. Transplacental passage of chlordiazepoxide. Br Med J, 2:729. 

Guaifenesin

Selected References:

  • Flurazepam Drug Label. 2023. https://www.drugs.com/pro/flurazepam.html
  • Gentile, S. 2015. Pharmacological management of borderline personality disorder in a pregnant woman with a previous history of alcohol addiction: a case report. Clin Drug Investig, 35(11):761-763.
  • Kelly LE, et al. 2012. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr, 161:448-451.
Guaifenesin
1 ديسمبر، 2024		 صفحة {PAGENO} من {PAGETOTAL}